Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study' by Marotte et al

Ann Rheum Dis. 2020 Jul;79(7):e82. doi: 10.1136/annrheumdis-2019-215609. Epub 2019 May 9.
No abstract available

Keywords: DMARDs (biologic); anti-TNF; pharmacokinetics; rheumatoid arthritis.

Publication types

  • Comment

MeSH terms

  • Adalimumab
  • Antirheumatic Agents*
  • Arthritis, Rheumatoid*
  • Humans
  • Recurrence
  • Tumor Necrosis Factor Inhibitors


  • Antirheumatic Agents
  • Tumor Necrosis Factor Inhibitors
  • Adalimumab